Business
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 /
About this update from Amphastar Pharmaceuticals, Inc.
[{"type":"text","content":"Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. (\"IMS\"), a subsidiary of Amphastar Pharmaceuticals, Inc. (\"Amphastar\") received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (\"FDA\"). This prestigious award recognizes IMS significant efforts in preventing and alleviating critical drug shortages, ensuring that patients have access to essential medications.IMS is being recognized for its efforts to mitigate and resolve the long-standing drug shortage of epinephrine injection, 0.1 mg/mL syringes, including submitting and obtaining approval of a new drug application for epinephrine injection.The FDA Drug Shortage Assistance Award honors companies that show a strong commitment to public health and quality manufacturing by taking proactive measures to address drug supply challenges.\"We are deeply honored to receive this recognition from the FDA,\" said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. \"Our team is dedicated to ensuring a reliable supply of critical medications, and this award validates our ongoing efforts to prioritize patient needs. We understand the importance of consistent access to medicine, and we will continue to work diligently to prevent shortages.\"Drug shortages pose a substantial public health threat, delaying and in some cases even denying, critically needed care for patients. Working with drug manufacturers, the FDA helped prevent 145 drug shortages in CY 2017, 160 shortages in CY 2018, 154 in CY 2019, 199 in CY 2020, and 317 in CY 2021, 222 in CY 2022, and 236 in CY 2023.Amphastar and its subsidiaries are committed to working closely with the FDA and other stakeholders to tackle drug supply issues and ensure that essential medications are available to patients across the country.Pipeline InformationThe Company currently has four abbreviated new drug applications (\"ANDAs\") on file with the FDA targeting products with a market size exceeding $2 billion, along with four biosimilar products in development targeting products with a market size exceeding $7 billion, and two generic products in development targeting products with a market size of ove...